Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · 2A
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
Source: Senate LDA
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
Mikaela Naylon Give Kids a Chance Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Accelerating Kids’ Access to Care Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM
Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.5371: CONTINUING APPROPRIATIONS, ARGICULTURE, LEGISLATIVE BRANCH, MILITARY CONSTRUCTION AND VETERANS AFFAIRS, AND EXTENSIONS ACT, 2026; PROVISIONS RELATED TO JOINT EXPLANTATORY STATEMENT, DIV. B
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
Give Kids a Chance Act of 2025
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
The 340B PATIENTS Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Patient Access Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Patient Access Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Accelerating Kids’ Access to Care Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
Creating Hope Reauthorization Act of 2024
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, MEDICARE PART B HEMOPHILIA FURNISHING FEE, MINIMUM MEDICAID REBATE PERCENTAGE FOR CLOTTING FACTOR, MEDICAID ACCESS TO OUT OF STATE PROVIDERS
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, MEDICAID DRUG REBATE PROGRAM, MEDICAID ACCESS TO OUT OF STATE PROVIDERS
Medicaid VBPs for Patients Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 3131: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Promising Pathway Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 3131: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Providing Realistic Opportunity To Equal and Comparable Treatment for Rare Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 3131: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Promising Pathway Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 3131: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Consolidated Appropriations Act, 2023
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
BENEFIT Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
BENEFIT Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
Newborn Screening Saves Lives Reauthorization Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
Inflation Reduction Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B HR 5989: PRECISION MEDICINE ANSWERS FOR KIDS TODAY ACT; ALL PROVISIONS OF THE BILL HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION SENATE DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
Inflation Reduction Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B
Precision Medicine Answers for Kids Today Act
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B HR 5989: PRECISION MEDICINE ANSWERS FOR KIDS TODAY ACT; ALL PROVISIONS OF THE BILL HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION SENATE DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Helping Experts Accelerate Rare Treatments Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Helping Experts Accelerate Rare Treatments Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Accelerated Approval Integrity Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Accelerated Approval Integrity Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
Accelerating Access for Patients Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Accelerating Access for Patients Act of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B HR 5989: PRECISION MEDICINE ANSWERS FOR KIDS TODAY ACT; ALL PROVISIONS OF THE BILL HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION SENATE DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT: ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION
Food and Drug Amendments of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Food and Drug Amendments of 2022
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
Lower Costs, More Cures Act of 2021
Client: BIOMARIN PHARMACEUTICAL INC. · Firm: BIOMARIN PHARMACEUTICAL INC.
HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT: ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · 2A
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · second_quarter · Q2
GENERAL DISCUSSIONS REGARDING MEDICAID GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING PATIENT EXPERIENCE DATA GENERAL DISCUSSIONS REGARDING RECOMMENDED UNIFORM SCREENING PANEL (RUSP) CONDITION ADDITION GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND TESTING
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION GENERAL DISCUSSIONS REGARDING UTILIZATION MANAGEMENT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2026 · first_quarter · Q1
GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) FOREIGN REFERENCE PRICING GENERAL DISCUSSIONS REGARDING MEDICAID PRIOR AUTHORIZATION
GENERAL DISCUSSIONS REGARDING SECTION 232 INVESTIGATION ON BIOPHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING GENETIC TESTING AND NEWBORN SCREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION GENERAL DISCUSSIONS RELATED TO TARIFFS ON PHARMACEUTICALS GENERAL DISCUSSIONS RELATED TO METABOLIC DISORDER PUBLIC HEALTH CAMPAIGN GENERAL DISCUSSIONS RELATED TO RARE DISEASE DRUG DEVELOPMENT
Filing targets: Commerce, Dept of (DOC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · fourth_quarter · Q4
H.R.5371: CONTINUING APPROPRIATIONS, ARGICULTURE, LEGISLATIVE BRANCH, MILITARY CONSTRUCTION AND VETERANS AFFAIRS, AND EXTENSIONS ACT, 2026; PROVISIONS RELATED TO JOINT EXPLANTATORY STATEMENT, DIV. B
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG REFERENCE PRICING
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Filing targets: Commerce, Dept of (DOC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · third_quarter · Q3
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG EXCLUSIVITY
H.R.1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S.932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING GENETIC SREENING AND NEWBORN SREENING GENERAL DISCUSSIONS REGARDING ORPHAN DRUGS GENERAL DISCUSSIONS RELATED TO MOST-FAVORED-NATION (MFN) DRUG PRICING GENERAL DISCUSSIONS RELATED TO THE PRIORITY REVIEW VOUCHER PROGRAM
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · second_quarter · Q2
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING INFLATION REDUCTION ACT AND ORPHAN DRUGS GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING GENETIC SCREENING AND NEWBORN SCREENING
H.R. 1: ONE BIG BEAUTIFUL BILL ACT; PROVISIONS RELATED TO TITLE VII, SUBTITLE B H.R. 946: ORPHAN Cures Act; ALL PROVISIONS H.R. 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 752: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S. 1637: MEDICAID VBPS FOR PATIENTS (MVP) Act; ALL PROVISIONS S. 1862: ORPHAN Cures Act; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2025 · first_quarter · Q1
HR 1262: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION S 932: GIVE KIDS A CHANCE ACT OF 2025; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM REAUTHORIZATION GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT, HEALTH AND HUMAN SERVICES (HHS) RESTRUCTURING, MANUFACTURER-SPONSORED GENETIC SCREENING, PRIORITY REVIEW VOUCHER (PRV) EXTENSION, MEDICAID, NEWBORN SCREENING
HR 1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS OF THE BILL S 752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID REFORM
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · fourth_quarter · Q4
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT: ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0, AND ORPHAN DRUG ACT
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · third_quarter · Q3
HR 830: HELP ENSURE LOWER PATIENT (HELP) COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL HR 8574: 340B AFFORDABLE CARE FOR COMMUNITIES AND ENSURING A STRONG SAFETY-NET (ACCESS) ACT; ALL PROVISIONS OF THE BILL HR 9184: PATIENT ACCESS ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENETIC SCREENING, LONG TERM FOLLOW UP, CURES 3.0
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDER TELEHEALTH
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · second_quarter · Q2
HR 830: HELP ENSURE LOWER PATIENT COPAYS ACT; ALL PROVISIONS OF THE BILL HR 2369: VERIFYING ACCURATE LEADING-EDGE IVCT DEVELOPMENT ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2630: SAFE STEP ACT; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024; ALL PROVISIONS OF THE BILL S 4583: A BILL TO AMEND THE FEDERAL FOOD, DRUG, AND COSMETIC ACT TO EXTEND THE AUTHORITY OF THE SECRETARY OF HEALTH AND HUMAN SERVICES TO ISSUE PRIORITY REVIEW VOUCHERS TO ENCOURAGE TREATMENTS FOR RARE PEDIATRIC DISEASES; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH EQUITY
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL HR 4758: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 4204: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL S 2372: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2024 · first_quarter · Q1
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND ACCESS TO OUT OF STATE PROVIDERS
HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CURES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 7384: CREATING HOPE REAUTHORIZATION ACT OF 2024: ALL PROVISIONS OF THE BILL HR 7635: THE 340B PHARMACEUTICAL ACCESS TO INVEST IN ESSENTIAL, NEEDED TREATMENTS & SUPPORT ACT OF 2024 (PATIENTS ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · fourth_quarter · Q4
HR 2369: VALID ACT OF 2023; ALL PROVISIONS OF THE BILL HR 2666: MEDICAID VBPS FOR PATIENTS ACT (MVP ACT); PROVISIONS RELATED TO OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA) HR 4408: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL S 1906: PROMISING PATHWAY ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING 340B DRUG PRICING PROGRAM REFORM, RARE DISEASE GENE THERAPY ACCESS, CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) PROPOSED PRICE JUSTIFICATION SURVEY, HEMOPHILIA GENE THERAPY, RARE DISEASE DRUG DEVELOPMENT
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL HR 5539: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL HR 6094: PROVIDING REALISTIC OPPORTUNITY TO EQUAL AND COMPARABLE TREATMENT FOR RARE ACT (PROTECT RARE ACT); ALL PROVISIONS OF THE BILL S 3131: OPTIMIZING RESEARCH PROGRESS HOPE AND NEW CARES ACT (ORPHAN CURES ACT); ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · third_quarter · Q3
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY, RARE DISEASE EXPERTS ON FOOD AND DRUG ADMINISTRATION REVIEW TEAMS, RARE DISEASE DIAGNOSIS, AND OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA)
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, MEDICARE PART B HEMOPHILIA FURNISHING FEE, MINIMUM MEDICAID REBATE PERCENTAGE FOR CLOTTING FACTOR, MEDICAID ACCESS TO OUT OF STATE PROVIDERS
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · second_quarter · Q2
HR 2666: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, MEDICAID DRUG REBATE PROGRAM, MEDICAID ACCESS TO OUT OF STATE PROVIDERS
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY GENERAL DISCUSSIONS REGARDING VALUE BASED ARRANGEMENTS (VBA)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2023 · first_quarter · Q1
GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY GENERAL DISCUSSIONS REGARDING OUTCOME BASED ARRANGEMENTS (OBA) AND VALUE BASED ARRANGEMENTS (VBA)
(NO BILL #) PRECISION MEDICINE ANSWERS FOR KIDS TODAY ACT; ALL PROVISIONS OF THE DRAFT (NO BILL #) MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES AND MEDICAID DRUG REBATE PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · fourth_quarter · Q4
HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL (HR 2617) P.L. 117-328: CONSOLIDATED APPROPRIATIONS ACT, 2023: PROVISIONS RELATED TO SECTIONS 3107, 3202, 3210, 3601-3607, 3629 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FEDERAL DRUG ADMINISTRATION AND EUROPEAN MEDICINES AGENCY DRUG APPROVAL GENERAL DISCUSSIONS REGARDING ANTI-KICKBACK SAFE HARBOR FOR PATIENT TRAVEL COSTS GENERAL DISCUSSIONS REGARDING BUDGET RIDERS, ORPHAN DRUG ACT TAX CREDIT, AND VETERANS BENEFITS ADMINISTRATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · third_quarter · Q3
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING RARE DISEASES AND VETERANS BENEFITS ADMINISTRATIONS
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · second_quarter · Q2
HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT: ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022; ALL PROVISIONS OF THE BILL HR 7667: FOOD AND DRUG AMENDMENTS OF 2022; PROVISIONS RELATED TO TITLE V, SECTIONS 703 AND 804 S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL S 4071: HELPING EXPERTS ACCELERATE RARE TREATMENTS ACT OF 2022; ALL PROVISIONS OF THE BILL S 4348: FOOD AND DRUG ADMINISTRATION SAFETY AND LANDMARK ADVANCEMENTS ACT OF 2022 (FDASLA ACT); PROVISIONS RELATED TO SECTION 506 GENERAL DISCUSSIONS REGARDING ISSUES AFFECTING GENETIC BONE DISORDERS GENERAL DISCUSSIONS REGARDING HEMOPHILIA GENE THERAPY
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2022 · first_quarter · Q1
HR 4472: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407 HR 6584: DIVERSE AND EQUITABLE PARTICIPATION IN CLINICAL TRIALS (DEPICT) ACT; ALL PROVISIONS OF THE BILL HR 6888: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6963: ACCELERATED APPROVAL INTEGRITY ACT OF 2022; ALL PROVISIONS OF THE BILL HR 6996: ACCELERATING ACCESS FOR PATIENTS ACT OF 2022: ALL PROVISIONS OF THE BILL S 373: BETTER EMPOWERMENT NOW TO ENHANCE FRAMEWORK AND IMPROVE TREATMENTS (BENEFIT) ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING VALUE-BASED PAYMENT ARRANGEMENTS (VBA)
S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · fourth_quarter · Q4
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102, 139201, AND THE ORPHAN DRUG ACT TAX CREDIT
HR 785: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL S 2313: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
HR 842: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 6000: CURES 2.0 ACT: PROVISIONS RELATED TO SECTIONS 203, 204, 303-309, 402, 403, 407, AND RARE DISEASES S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE 21ST CENTURY CURES ACT 2.0
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · third_quarter · Q3
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTION 138141 GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE OUTCOME-BASED ARRANGEMENTS
S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO OUTCOMES-BASED AGREEMENTS FOR GENE THERAPY (SECTIONS 121-123) GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS FOR RARE DISEASE THERAPIES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · second_quarter · Q2
HR 482: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL HR 1184: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEART) ACT OF 2021; ALL PROVISIONS OF THE BILL S 350: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2021; ALL PROVISIONS OF THE BILL S 373: BENEFIT ACT OF 2021; PROVISIONS RELATED TO RARE DISEASES S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO VALUE BASED ARRANGEMENTS GENERAL DISCUSSIONS RELATED TO THE 21ST CENTURY CURES ACT 2.0 GENERAL DISCUSSIONS RELATED TO THE ORPHAN DRUG ACT
HR 2623: CAMERON'S LAW; ALL PROVISIONS OF THE BILL
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2021 · first_quarter · Q1
H.R. 785: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESA: ALL PROVISIONS OF THE BILL
GENERAL DISCUSSIONS REGARDING THE VALUE BASED ARRANGEMENTS AND ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING CENTER OF DISEASE CONTROL APPROPRIATIONS FOR LONG-TERM FOLLOW-UP FOR METABOLIC DISORDERS
GENERAL DISCUSSIONS REGARDING GENE THERAPY ACCESS AND MEDICAID ACCESS
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · fourth_quarter · Q4
H.R. 4225: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO, AND ANA LUCIA BUESO BARRERA; ALL PROVISIONS OF THE BILL S. 2612: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
H.R. 5882: GENE THERAPY PAYMENT ACT; ALL PROVISIONS OF THE BILL S. 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; ALL PROVISIONS OF THE BILL
H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING HEALTH INNOVATION; VALUE BASED ARRANGEMENTS; FDA BREAKTHROUGH THERAPY DESIGNATION AND RESPONSE LETTER; 21ST CENTURY CURES ACT 2.0
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · third_quarter · Q3
H.R. 5882: GENE THERAPY PAYMENT ACT; PROVISIONS RELATED TO GENE THERAPY ACCESS S. 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; PROVISIONS RELATED TO SECTION 208-GENE THERAPY ACCESS
H.R. 4225: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO, AND ANA LUCIA BUESO BARRERA; ALL PROVISIONS OF THE BILL S. 2612: FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, AND KARLA MARIA BARRERA DE BUESO; ALL PROVISIONS OF THE BILL
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT; ALL PROVISIONS OF THE BILL H.R. 7567: HELPING EXPERTS ACCELERATE RARE TREATMENTS (HEARTS) ACT OF 2020; ALL PROVISIONS OF THE BILL H.R. 7647: TO PROVIDE FOR A COVID-19-RELATED DELAY REGARDING ANNUAL LIMITATION ON COST-SHARING FOR GROUP HEALTH PLANS AND INDIVIDUAL AND SMALL GROUP HEALTH INSURANCE COVERAGE; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S. 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING FOOD & DRUG ADMINISTRATION'S COMPLETE RESPONSE LETTER; BREAKTHROUGH THERAPY PROGRAM; HEALTH INNOVATION; NEWBORN SCREENING; VALUE BASED ARRANGEMENTS
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · second_quarter · Q2
MEDICAID PROGRAM: SUPPORTING VALUE-BASED PURCHASING FOR DRUGS COVERED IN MEDICAID; GENERAL DISCUSSIONS REGARDING VALUE-BASED PURCHASING ARRANGEMENTS H.R. 5882: GENE THERAPY PAYMENT ACT; ALL PROVISIONS OF THE BILL S 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; PROVISIONS RELATED TO SECTION 208 (GENE THERAPY)
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 4010: CREATING HOPE REAUTHORIZATION ACT; ALL PROVISIONS OF THE BILL CONTROLLED SUBSTANCE UTILIZATION REVIEW AND EVALUATION SYSTEM 2.0: GENERAL DISCUSSIONS REGARDING INNOVATION GENERAL DISCUSSIONS REGARDING GENE THERAPY AND OFFICE OF BIOTECHNOLOGY ACTIVITIES GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2020 · first_quarter · Q1
H.R. 5882: GENE THERAPY PAYMENT ACT; ALL PROVISIONS OF THE BILL S 2326: NEW OPPORTUNITIES FOR VALUE THAT EXTEND LIVES (NOVEL) ACT OF 2019; ALL PROVISIONS OF THE BILL S 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; PROVISIONS RELATED TO SECTION 208
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 6238: CAMERON'S LAW; ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESCRIPTION DRUG PRICING AND GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · fourth_quarter · Q4
H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM H.R. 4667: BIOMEDICAL INNOVATION EXPANSION ACT OF 2019; PROVISIONS RELATED TO NATIONAL INSTITUTES OF HEALTH FUNDING FOR RARE DISEASE RESEARCH H.R. 4712: FAIRNESS IN ORPHAN DRUG EXCLUSIVITY ACT: ALL PROVISIONS OF THE BILL S 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA (PKU) LOST TO FOLLOW UP GENERAL DISCUSSIONS REGARDING 21ST CENTURY CURES 2.0; PROVISIONS RELATED TO PATIENT ACCESS TO INNOVATION THERAPIES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · third_quarter · Q3
S. 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; PROVISIONS RELATED TO SECTION 208 AND GENE THERAPY GENERAL DISCUSSIONS REGARDING GENE THERAPY
H.R. 3: LOWER DRUG COSTS NOW ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2069: SPIKE ACT; ALL PROVISIONS OF THE BILL H.R. 2296: MORE EFFICIENT TOOLS TO REALIZE INFORMATION FOR CONSUMERS ACT; ALL PROVISIONS OF THE BILL H.R. 2375: PRESERVE ACCESS TO AFFORDABLE GENERICS AND BIOSIMILARS ACT; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 3235: ACCESS TO GENETIC COUNSELOR SERVICES ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 4439: CREATING HOPE REATHORIZATION ACT; ALL PROVISIONS OF THE BILL S. 2158: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING THE PRESCRIPTION DRUG PRICING REDUCTION ACT'S OUTCOMES BASED AGREEMENTS GENERAL DISCUSSIONS RELATED TO PHENYLKETONURIA (PKU) LOST TO FOLLOW UP
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · second_quarter · Q2
H.R. 2113: PRESCRIPTION DRUG STAR ACT; ALL PROVISIONS OF THE BILL H.R. 2296: FAIR DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL H.R. 2507: NEWBORN SCREENING SAVES LIVES REAUTHORIZATION ACT OF 2019; ALL PROVISIONS OF THE BILL S 474: STOPPING THE PHARMACEUTICAL INDUSTRY FROM KEEPING DRUGS EXPENSIVE (SPIKE) ACT OF 2019; ALL PROVISIONS OF THE BILL S. 1391 FAIR ACCOUNTABILITY AND INNOVATIVE RESEARCH (FAIR) DRUG PRICING ACT OF 2019; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT AND TAX CREDIT (NOT YET INTRODUCED) GENERAL DISCUSSIONS REGARDING PATIENT AFFORDABILITY, VALUE & EFFICIENCY (PAVE) ACT; ALL PROVISIONS OF THE DRAFT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2019 · first_quarter · Q1
H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING
H.RES. 242: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, CELEBRATING THE OVER 750 NEW ORPHAN THERAPIES APPROVED SINCE ITS CREATION, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASE; ALL PROVISIONS OF THE RESOLUTION H.R. 1046: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL S. 377: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2019; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY AND VALUE BASED CONTRACTING GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING RE-AUTHORIZATION ACT GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING HEALTH CARE FINANCING
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · fourth_quarter · Q4
H.RES. 1154: AFFIRMING THE IMPORTANCE OF THE ORPHAN DRUG ACT, APPLAUDING ITS LIFESAVING CONTRIBUTIONS OVER ITS 35-YEAR HISTORY, AND RECOGNIZING THE NEED TO CONTINUE SUPPORTING RESEARCH AND DEVELOPMENT FOR RARE DISEASES; ALL PROVISIONS OF THE RESOLUTION GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING THE ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING NEWBORN SCREENING GENERAL DISCUSSION REGARDING ADVANCE NOTICE OF PROPOSED RULE MAKING (ANPRM): INTERNATIONAL PRICING INDEX MODEL FOR MEDICARE PART B DRUGS GENERAL DISCUSSIONS REGARDING HEALTH EDUCATION
H.R. 3325: ACE KIDS ACT; ALL PROVISIONS OF THE BILL H.R. 6524: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 428: ACE KIDS ACT OF 2017; ALL PROVISIONS OF THE BILL S 2415: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · third_quarter · Q3
H.R. 6801: RARE DISEASE FUND (RaD) ACT OF 2018; ALL PROVISION OF THE BILL GENERAL DISCUSSIONS REGARDING GENE THERAPY GENERAL DISCUSSIONS REGARDING PHENYLKETONURIA(PKU) EDUCATION AND OUTREACH GENERAL DISCUSSIONS REGARDING IMPACT OF FOOD AND DRUG ADMINISTRATION REORGANIZATION ON RARE DISEASE CLINICAL GENERAL DISCUSSIONS REGARDING AMERICAN PATIENTS FIRST: BLUEPRINT TO LOWER DRUG PRICES AND REDUCE OUT OF POCKET COSTS
H.R. 3325: ACE KIDS ACT; ALL PROVISIONS OF THE BILL H.R. 6505: MEDICARE NEGOTIATION AND COMPETITIVE LICENSING ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 6524: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL S 428: ACE KIDS ACT; ALL PROVISIONS OF THE BILL S 2415: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS OF THE BILL
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · second_quarter · Q2
GENERAL DISCUSSIONS REGARDING MEDICAID OUT OF STATE PROVIDERS, MEDICAID 1115 WAIVERS AND PRIOR AUTHORIZATION AND MEDICARE PART B AND D COVERAGE OF RARE DISEASE THERAPIES
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL H.R. 5115: RARE dISEASE ADVANCEMENT, RESEARCH, AND EDUCATION (RARE) ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL GENERAL DISCUSSIONS REGARDING PRESERVATION OF ORPHAN DRUG ACT GENERAL DISCUSSIONS REGARDING FOOD AND DRUG ADMINISTRATION DISEASE EDUCATION GENERAL DISCUSSIONS REGARDING GENE THERAPY, RARE BRAIN DISORDER, FOOD AND DRUG ADMINISTRATION ADVISORY COMMITTEE MEETINGS AND PRESCRIPTION DRUG COST
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2018 · first_quarter · Q1
H.R. 5247: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2018; ALL PROVISIONS OF THE BILL S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; ALL PROVISIONS OF THE BILL ORPHAN DRUG ACT (NO BILL); PROVISIONS RELATED TO ORPHAN DRUG CREDIT, EXCLUSIVITY, DESIGNATION, AND EDUCATION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · fourth_quarter · Q4
GENERAL DISCUSSIONS REGARDING SECTION 1115 WAIVERS, MEDICAID PRIOR AUTHORIZATION AND OUT OF STATE MEDICAID PROVIDERS
H.R. 1: AN ACT TO PROVIDE FOR RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL YEAR 2018; PROVISIONS RELATED TO THE ORPHAN DRUG TAX CREDIT S. 204: TRICKETT WENDLER, FRANK MONGIELLO, JORDAN MCLINN, AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE
H.R. 1: AN ACT TO PROVIDE THE RECONCILIATION PURSUANT TO TITLES II AND V OF THE CONCURRENT RESOLUTION ON THE BUDGET FOR FISCAL 2018; PROVISIONS RELATED TO ORPHAN DRUG TAX CREDIT
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · third_quarter · Q3
H.R.878: RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS AND USE OF OUTCOMES. H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017 (SENATE DRAFT: BETTER CARE RECONCILIATION ACT OF 2017); PROVISIONS RELATED TO MEDICAID, BLOCK GRANTS AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; ALL PROVISIONS OF THE BILL. S. 204: TRICKETT WENDLER, FRANK MOGIELLO, JORDAN MCLINN AND MATTHEW BELLINA RIGHT TO TRY ACT OF 2017; PROVISIONS RELATED TO EXPANDED ACCESS, USE OF OUTCOMES AND LANGUAGE. S. 586: CORPORATE TAX DODGING PREVENTION ACT; PROVISIONS RELATED TO MEDICAID AND BLOCK GRANTS. S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUGS AND EXPANDED ACCESS.
GENERAL DISCUSSIONS REGARDING TAX REFORM AND THE ORPHAN DRUG TAX CREDIT.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · second_quarter · Q2
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID, WAIVERS FOR ESSENTIAL HEALTH BENEFITS AND COMMUNITY RATING DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; ALL PROVISIONS OF THE BILL H.R. 2430: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT S 934: FDA REAUTHORIZATION ACT OF 2017; PROVISIONS RELATED TO ORPHAN DRUG ACT, RIGHT TO TRY AND RACE ACT DRAFT BILL: BETTER CARE RECONCILIATION ACT; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS DISCUSSIONS REGARDING THE ORPHAN DRUG ACT; PROVISIONS RELATED TO VALUE OF RARE DISEASE THERAPIES
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · 1A
GENERAL DISCUSSION REGARDING THE PRESERVATION OF SECTION 45C OF THE INTERNAL REVENUE CODE. GENERAL DISCUSSION REGARDING TAX CREDITS.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID REFORM. S 222: OBAMACARE REPLACEMENT ACT; PROVISIONS RELATED TO MEDICAID REFORM. GENERAL DISCUSSION REGARDING FOOD AND DRUG ADMINISTRATION IMPLEMENTATION OF MEDICAID REBATE FOR PEDIATRIC DRUGS.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2017 · first_quarter · Q1
GENERAL DISCUSSIONS REGARDING CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM.
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID FUNDING. SPIKE ACT OF 2017 (DRAFT BILL): PROVISIONS RELATED TO PRESCRIPTION DRUG TRANSPARENCY. GENERAL DISCUSSION REGARDING PRODUCT LAUNCH. GENERAL DISCUSSION REGARDING THE ORPHAN DRUG ACT. GENERAL DISCUSSION REGARDING ACCELERATED APPROVAL FOR SOMATIC CELL GENE THERAPY.
GENERAL DISCUSSION REGARDING THE PRESERVATION OF SECTION 45C OF THE INTERNAL REVENUE CODE. GENERAL DISCUSSION REGARDING TAX CREDITS.
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · fourth_quarter · Q4
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 34: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION, REGENERATIVE MEDICINE, PATIENT EXPERIENCE DATA, AND REAL WORLD EVIDENCE DATA H.R. 971: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION H.R. 1537: ADVANCING HOPE ACT OF 2015; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT: PROVISIONS RELATED TO THIRD PARTY PREMIUM ASSISTANCE S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO HOME INFUSION BENEFIT S 1421: ORPHAN PRODUCT EXTENSIONS NOW ACCELERATING CURES AND TREATMENTS ACT OF 2015; PROVISIONS RELATED TO PATENT EXTENSION S 1597: PATIENT-FOCUSED IMPACT ASSESSMENT ACT OF 2016; PROVISIONS RELATED TO PATIENT ENGAGEMENT AND FOOD AND DRUG ADMINISTRATION REQUIREMENTS S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO COMBINATION PRODUCT REVIEW S 1878: ADVANCING HOPE ACT OF 2016; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM EXTENSION
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIOMARIN PHARMACEUTICAL INC. via BIOMARIN PHARMACEUTICAL INC.
2016 · third_quarter · Q3
H.R. 546: ACE KIDS ACT OF 2015; PROVISIONS RELATED TO MEDICAID ACCESS TO THERAPY H.R. 605: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO MEDICARE ACCESS TO THERAPY S 298: ACE KIDS ACT OF 2015; PROVISIONS RELATED TO MEDICAID ACCESS TO THERAPY S 275: MEDICARE HOME INFUSION SITE OF CARE ACT OF 2015; PROVISIONS RELATED TO MEDICARE ACCESS TO THERAPY
H.R. 6: 21ST CENTURY CURES ACT; PROVISIONS RELATED TO RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER PROGRAM H.R. 3012: RIGHT TO TRY ACT OF 2015; PROVISIONS RELATED TO THE RIGHT TO TRY H.R. 3742: ACCESS TO MARKETPLACE INSURANCE ACT; PROVISIONS RELATED TO PATIENT ASSISTANCE S 1767: COMBINATION PRODUCT REGULATORY FAIRNESS ACT OF 2016; PROVISIONS RELATED TO REGULATION OF COMBINATION PRODUCTS S 1878: ADVANCING HOPE ACT OF 2016; ALL PROVISIONS OF THE BILL S 2912: TRICKETT WENDLER RIGHT TO TRY ACT OF 2016; PROVISIONS RELATED TO RIGHT TO TRY
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R.1509: ACCELERATING KIDS' ACCESS TO CARE ACT OF 2025; ALL PROVISIONS S.752: ACCELERATING KIDS' ACCESS TO CARE ACT; ALL PROVISIONS S.1637: MVP ACT; ALL PROVISIONS GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM GENERAL DISCUSSIONS REGARDING FOREIGN DRUG REFERENCE PRICING
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Filing targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING TARIFFS ON PHARMACEUTICALS
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG TAX CREDIT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Government Accountability Office (GAO), HOUSE OF REPRESENTATIVES, SENATE
P.L. 117-169: INFLATION REDUCTION ACT OF 2022 (HR 5376); PROVISIONS RELATED TO TITLE I, SUBTITLES A AND B HR 5989: PRECISION MEDICINE ANSWERS FOR KIDS TODAY ACT; ALL PROVISIONS OF THE BILL HR 7389: MEDICAID VBPS FOR PATIENTS (MVP) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISION RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING TELEMENTAL HEALTH DISCUSSION SENATE DRAFT GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES, TELEHEALTH, AND HOME INFUSION GENERAL DISCUSSIONS REGARDING MEDICAID DRUG REBATE PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
HR 5376: BUILD BACK BETTER ACT; PROVISIONS RELATED TO SECTIONS 138121, 138126, 138127, 138141, 139001, 139101, 139102 AND 139201 S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO SECTIONS 121-123 GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS TO RARE DISEASE THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING CENTERS FOR DISEASE CONTROL AND PREVENTION APPROPRIATIONS FOR LONG TERM FOLLOW-UP FOR METABOLIC DISORDERS
S 1798: TELEHEALTH IMPROVEMENT FOR KIDS' ESSENTIAL SERVICES (TIKES) ACT; ALL PROVISIONS OF THE BILL S 2164: LOWER COSTS, MORE CURES ACT OF 2021; PROVISIONS RELATED TO OUTCOMES-BASED AGREEMENTS FOR GENE THERAPY (SECTIONS 121-123) GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS FOR RARE DISEASE THERAPIES
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING ORPHAN DRUG CREDIT
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
LABOR, HEALTH AND HUMAN SERVICES APPROPRIATIONS: GENERAL DISCUSSIONS REGARDING METABOLIC DISORDER SURVEILLANCE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 4225: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA, KARLA MARIA BARRERA DE BUESO AND ANA LUCIA BUESO BARRERA; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM S 2612: A BILL FOR THE RELIEF OF MARIA ISABEL BUESO BARRERA, ALBERTO BUESO MENDOZA AND KARLA MARIA BARRERA DE BUESO; PROVISIONS RELATED TO EXTEND DEFERRED PROGRAM
H.R. 3: ELIJAH E. CUMMINGS LOWER DRUG COSTS NOW ACT; PROVISIONS RELATED TO MULLIN-SCHRADER GENE THERAPY AMENDMENT S. 2543: PRESCRIPTION DRUG PRICING REDUCTION ACT OF 2019; PROVISIONS RELATED TO SECTION 208
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING THE U.S.-MEXICO-CANADA AGREEMENT'S BIOLOGICS EXCLUSIVITY
GENERAL DISCUSSIONS REGARDING DEFERRED ACTION FOR MEDICAL AND DEFERRED ACTION PROGRAM
Filing targets: HOUSE OF REPRESENTATIVES, Homeland Security, Dept of (DHS), SENATE, U.S. Immigration & Customs Enforcement (ICE)
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID AND WAIVERS FOR ESSENTIAL HEALTH BENEFITS. GENERAL DISCUSSIONS REGARDING OUTPATIENT PROSPECTIVE PAYMENT SYSTEM PROPOSED RULE CY18; 340B SALES IN OUTPATIENT PROSPECTIVE PAYMENT SYSTEM. GENERAL DISCUSSIONS REGARDING MEDICAID ACCESS; OUT-OF-STATE PROVIDERS, PRIOR AUTHORIZATION AND SECTION 1115.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
GENERAL DISCUSSIONS REGARDING TAX REFORM AND THE ORPHAN TAX CREDIT
Filing targets: HOUSE OF REPRESENTATIVES, Office of the Vice President of the United States, SENATE
GENERAL DISCUSSIONS REGARDING CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAM.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
H.R. 1628: AMERICAN HEALTH CARE ACT OF 2017; PROVISIONS RELATED TO MEDICAID REFORM. S 222: OBAMACARE REPLACEMENT ACT; PROVISIONS RELATED TO MEDICAID REFORM. GENERAL DISCUSSION REGARDING FOOD AND DRUG ADMINISTRATION IMPLEMENTATION OF MEDICAID REBATE FOR PEDIATRIC DRUGS.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE